Company Announcement no. 23/2007 To: OMX Nordic Exchange Hørsholm, Denmark, September 10, 2007 LifeCycle Pharma A/S - Report Pursuant to the Danish Securities Trading Act, Section 28(a) Summary: Report of transactions in LifeCycle Pharma shares and related securities by persons discharging managerial responsibilities and persons/companies closely associated with these. Hørsholm, Denmark, September 10, 2007; Pursuant to the Danish Securities Trading Act, Section 28(a), LifeCycle Pharma A/S (OMX:LCP) is required, on a daily basis, to make public transactions in LifeCycle Pharma shares and related securities by persons discharging managerial responsibilities and persons/companies closely associated with these. -------------------------------------------------------------------------------- | Name | Michael Wolff Jensen | -------------------------------------------------------------------------------- | Reason for reporting | Chief Financial Officer | -------------------------------------------------------------------------------- | Issuer and ID code/ISIN | LifeCycle Pharma A/S / DK0060048148 | -------------------------------------------------------------------------------- | Type of transaction | Subscription of shares through | | | exercise of warrants | -------------------------------------------------------------------------------- | Date of transaction | September 10, 2007 | -------------------------------------------------------------------------------- | Relevant market | OMX, Nordic Exchange | -------------------------------------------------------------------------------- | Number of traded securities | 100,000 | -------------------------------------------------------------------------------- | Market value (subscription price) | DKK 738,250 | -------------------------------------------------------------------------------- About LifeCycle Pharma A/S ("LCP A/S"): LCP A/S, headquartered in Hørsholm, Denmark, is an emerging specialty pharmaceutical company focused on developing and commercializing a portfolio of innovative products in therapeutic areas such as cholesterol management, hypertension, organ transplantation and autoimmune diseases. LCP's proprietary MeltDose® technology, offers lower dosing, reduced side effects, improved safety and patient compliance, and reduced product development costs and times. LCP-FenoChol, a fenofibrate for the treatment of hyperlipidemia and hypertriglyceridemia, is LCP's first FDA approved product (approved in August 2007). LCP is listed on the OMX Nordic Exchange under the trading symbol (OMX:LCP). For further information, please visit www.lcpharma.com. Contact: Michael Wolff Jensen Executive Vice President and CFO Tel. +45 70 33 33 00 Mob. +45 40 74 62 44 Email. mwj@lcpharma.com ---oo0oo---
LifeCycle Pharma A/S - Report Pursuant to the Danish Securities Trading Act, Section 28(a)
| Source: Veloxis Pharmaceuticals A/S